IP Library › Granted Patent US 12,433,938
Granted Patent B2
US 12,433,938 · App. 17/117,099 · Granted Oct 7, 2025

Alkaline phosphatase polypeptides and methods of use thereof

Inventors: Walter C. Voegtli (Killingworth, CT); Michael Baranello (Boston, MA); Keith Bouchard (Boston, MA)
Assignee: Alexion Pharmaceuticals, Inc.
A61K38/465A61K9/0019A61K47/02A61P19/08C12N9/16C12Y301/03001C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,433,938
App. No.
17/117,099
Granted
Oct 7, 2025
Kind
B2
Abstract

Featured are polypeptides that include soluble alkaline phosphatases, mutants, fragments, fusion proteins thereof, and methods of use thereof, for treating bone mineralization disorders, such as hypophosphatasia (HPP), and symptoms thereof. The polypeptides include a soluble alkaline phosphatase (sALP) or fragment thereof, which is derived from a naturally occurring alkaline phosphatase (ALP).

Claims (21)

1. A polypeptide comprising: (1) a recombinant alkaline phosphatase having at least one mutation selected from the group consisting of E108S, E108T, E108Q, E108M, E108K, E108L, M384R, and L385T relative to SEQ ID NO: 1 and (2) a bone targeting moiety comprising from 3 to 30 consecutive aspartate or glutamate residues, wherein the polypeptide comprises an amino acid sequence with at least 90% sequence identity to any one of SEQ ID NOs: 72, 123, 155, or 177, wherein the original residue before mutation is shown in SEQ ID NO: 1, and the position numbers are relative to SEQ ID NOs: 1, 72, 123, 155, and 177.

2. The polypeptide of claim 1 , wherein the polypeptide further comprises a fragment crystallizable (Fc) region of an immunoglobulin.

3. The polypeptide of claim 2 , wherein the Fc region comprises IgG1, IgG2, IgG3, or IgG4, or a chimera thereof.

4. The polypeptide of claim 3 , wherein the Fc region comprises an IgG2/4 chimera.

5. The polypeptide of claim 4 , wherein the Fc region comprises the sequence of SEQ ID NO: 253 or has at least 85% sequence identity thereto.

6. The polypeptide of claim 1 , wherein the polypeptide comprises an amino acid sequence having at least 95% sequence identity to any one of SEQ ID NOs: 72, 123, 155, or 177.

7. The polypeptide of claim 1 , wherein the bone targeting moiety comprises Dn or En, wherein n=7 to 10.

8. The polypeptide of claim 7 , wherein the bone targeting moiety is

Dn and n=7 to 10.

9. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.

10. The pharmaceutical composition of claim 9 , wherein:

(a) the pharmaceutically acceptable carrier comprises sodium chloride and/or sodium phosphate;

(b) the composition comprises the polypeptide at a dosage of from 0.1 mg/ml to 10 mg/mL; and/or

(c) the composition is formulated in a volume of 0.1 mL to 50 mL.

11. The polypeptide of claim 1 , wherein the recombinant alkaline phosphatase has at least two, three, four, or five mutations selected from the group consisting of E108S, E108T, E108Q, E108M, E108K, E108L, M384R, and L385T relative to SEQ ID NO: 1.

12. The polypeptide of claim 6 , wherein the polypeptide comprises an amino acid sequence having at least 97% sequence identity to any one of SEQ ID NOs: 72, 123, 155, or 177.

13. The polypeptide of claim 12 , wherein the polypeptide comprises an amino acid sequence having at least 99% sequence identity to any one of SEQ ID NOs: 72, 123, 155, or 177.

14. The polypeptide of claim 13 , wherein the polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 72, 123, 155, or 177.

15. The polypeptide of claim 14 , wherein the polypeptide consists of the amino acid sequence of any one of SEQ ID NOs: 72, 123, 155, or 177.

16. The polypeptide of claim 14 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 123.

17. The polypeptide of claim 16 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 123.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2021
From: VOEGTLI, WALTER C.; BARANELLO, MICHAEL; BOUCHARD, KEITH
To: ALEXION PHARMACEUTICALS, INC.
Reel/Frame 055672/0094 →
Continuity (2)
Provisional Application 62945431 · Dec 9, 2019
Related Publication 20210169994A1 · Jun 10, 2021
References Cited (400)
US 5336759A · Matsuo et al. · 1994 [cited by applicant]
US 5338830A · Matsuo et al. · 1994 [cited by applicant]
US 5340920A · Matsuo et al. · 1994 [cited by applicant]
US 5352770A · Matsuo · 1994 [cited by applicant]
US 5428130A · Capon et al. · 1995 [cited by applicant]
US 5434133A · Tanaka et al. · 1995 [cited by applicant]
US 5583108A · Wei et al. · 1996 [cited by applicant]
US 5665704A · Lowe et al. · 1997 [cited by applicant]
US 5714147A · Capon et al. · 1998 [cited by applicant]
US 5767239A · Immer et al. · 1998 [cited by applicant]
US 5846932A · Lowe et al. · 1998 [cited by applicant]
US 5948761A · Seilhamer et al. · 1999 [cited by applicant]
US 5973134A · Matsuo et al. · 1999 [cited by applicant]
US 6020168A · Matsuo et al. · 2000 [cited by applicant]
US 6028055A · Lowe et al. · 2000 [cited by applicant]
US 6034231A · Tanaka et al. · 2000 [cited by applicant]
US 6290952B1 · Poelstra et al. · 2001 [cited by applicant]
US 6406697B1 · Capon et al. · 2002 [cited by applicant]
US 6407211B1 · Burnett, Jr. et al. · 2002 [cited by applicant]
US 6420384B2 · Weigele et al. · 2002 [cited by applicant]
US 6436386B1 · Roberts et al. · 2002 [cited by applicant]
US 6455495B1 · Orgel et al. · 2002 [cited by applicant]
US 6458579B2 · Hopwood et al. · 2002 [cited by applicant]
US 6525022B1 · Lowe et al. · 2003 [cited by applicant]
US 6541610B1 · Smith · 2003 [cited by applicant]
US 6743425B2 · Nakao · 2004 [cited by applicant]
US 6790649B1 · Crine et al. · 2004 [cited by applicant]
US 6818619B2 · Burnett, Jr. et al. · 2004 [cited by applicant]
US 6830885B1 · Lanctot et al. · 2004 [cited by applicant]
US 6849714B1 · Bridon et al. · 2005 [cited by applicant]
US 6887470B1 · Bridon et al. · 2005 [cited by applicant]
US 6905689B2 · Schneidinger et al. · 2005 [cited by applicant]
US 6946484B2 · Adams et al. · 2005 [cited by applicant]
US 7026293B2 · Kitakaze · 2006 [cited by applicant]
US 7033997B2 · Forssmann et al. · 2006 [cited by applicant]
US 7070974B1 · Desgroseillers et al. · 2006 [cited by applicant]
US 7105539B2 · Gravel et al. · 2006 [cited by applicant]
US 7112341B1 · Nagarajan et al. · 2006 [cited by applicant]
US 7179903B2 · McArthur et al. · 2007 [cited by applicant]
US 7256253B2 · Bridon et al. · 2007 [cited by applicant]
US 7271149B2 · Glaesner et al. · 2007 [cited by applicant]
US 7276481B2 · Golembo et al. · 2007 [cited by applicant]
US 7341838B2 · Buechler et al. · 2008 [cited by applicant]
US 7365091B2 · Gravel et al. · 2008 [cited by applicant]
US 7384917B2 · Burnett, Jr. et al. · 2008 [cited by applicant]
US 7399466B2 · Boileau · 2008 [cited by applicant]
US 7414107B2 · Larsen · 2008 [cited by applicant]
US 7425531B2 · Lanctot et al. · 2008 [cited by applicant]
US 7427498B2 · Crine et al. · 2008 [cited by applicant]
US 7470668B2 · Lanctot et al. · 2008 [cited by applicant]
US 7488713B2 · Vesely · 2009 [cited by applicant]
US 7527939B2 · Davey et al. · 2009 [cited by applicant]
US 7563769B2 · Bogin et al. · 2009 [cited by applicant]
US 7625564B2 · Wang et al. · 2009 [cited by applicant]
US 7642243B2 · Nakao et al. · 2010 [cited by applicant]
US 7648962B2 · James et al. · 2010 [cited by applicant]
US 7662773B2 · James et al. · 2010 [cited by applicant]
US 7678391B2 · Graham et al. · 2010 [cited by applicant]
US 7732406B2 · Mitrovic et al. · 2010 [cited by applicant]
US 7736653B2 · Kim et al. · 2010 [cited by applicant]
US 7754852B2 · Burnett, Jr. et al. · 2010 [cited by applicant]
US 7763712B2 · Crine et al. · 2010 [cited by applicant]
US 7803769B2 · Sullivan et al. · 2010 [cited by applicant]
US 7803901B2 · Burnett, Jr. et al. · 2010 [cited by applicant]
US 7825092B2 · Vesely · 2010 [cited by applicant]
US 7846900B2 · Vesely · 2010 [cited by applicant]
US 7858560B2 · Koster et al. · 2010 [cited by applicant]
US 7919591B2 · Sheffer et al. · 2011 [cited by applicant]
US 7943126B2 · Tomatsu et al. · 2011 [cited by applicant]
US 7960529B2 · Crine et al. · 2011 [cited by applicant]
US 8058242B2 · Alewood et al. · 2011 [cited by applicant]
US 8691208B2 · Tomatsu et al. · 2014 [cited by applicant]
US 9266939B2 · Crine et al. · 2016 [cited by applicant]
US 9650412B2 · Konstantinov et al. · 2017 [cited by applicant]
US 9650413B2 · Konstantinov et al. · 2017 [cited by applicant]
US 9908932B2 · Malanson et al. · 2018 [cited by applicant]
US 9988620B2 · Crine et al. · 2018 [cited by applicant]
US 10000532B2 · Crine et al. · 2018 [cited by applicant]
US 10052366B2 · Crine et al. · 2018 [cited by applicant]
US 10449236B2 · Marozsan et al. · 2019 [cited by applicant]
US 10603361B2 · Odrljin · 2020 [cited by applicant]
US 10988744B2 · Rajendran et al. · 2021 [cited by applicant]
US 11229686B2 · Pradhan et al. · 2022 [cited by applicant]
US 11352612B2 · Jaluria et al. · 2022 [cited by applicant]
US 11913039B2 · Godawat et al. · 2024 [cited by applicant]
US 12083169B2 · Voegtli et al. · 2024 [cited by applicant]
US 20020183276A1 · Millan et al. · 2002 [cited by applicant]
US 20030158132A1 · Kovesdi · 2003 [cited by applicant]
US 20040023916A1 · Millan et al. · 2004 [cited by applicant]
US 20040077537A1 · Schreiner · 2004 [cited by applicant]
US 20040234518A1 · Crine et al. · 2004 [cited by applicant]
US 20050113286A1 · Schreiner et al. · 2005 [cited by applicant]
US 20050142217A1 · Adams et al. · 2005 [cited by applicant]
US 20050202442A1 · Morris et al. · 2005 [cited by applicant]
US 20050244904A1 · Ng · 2005 [cited by applicant]
US 20050276796A1 · Tomatsu et al. · 2005 [cited by applicant]
US 20060014687A1 · Crine et al. · 2006 [cited by applicant]
US 20060019890A1 · Kapoun et al. · 2006 [cited by applicant]
US 20060074009A1 · James et al. · 2006 [cited by applicant]
US 20060110359A1 · Sanchez-Ramos et al. · 2006 [cited by applicant]
US 20060172929A1 · Rappold-Hoerbrand et al. · 2006 [cited by applicant]
US 20060228710A1 · Morris et al. · 2006 [cited by applicant]
US 20070041972A1 · Rother et al. · 2007 [cited by applicant]
US 20070042957A1 · Burnett et al. · 2007 [cited by applicant]
US 20070081984A1 · Tomatsu et al. · 2007 [cited by applicant]
US 20070081986A1 · Tomatsu et al. · 2007 [cited by applicant]
US 20070197434A1 · Nakao et al. · 2007 [cited by applicant]
US 20070281887A1 · Pan · 2007 [cited by applicant]
US 20070292966A1 · Prickett et al. · 2007 [cited by applicant]
US 20070293418A1 · Larsen · 2007 [cited by applicant]
US 20080032933A1 · Burnett et al. · 2008 [cited by applicant]
US 20080081768A1 · Watt et al. · 2008 [cited by applicant]
US 20080085862A1 · Kim et al. · 2008 [cited by applicant]
US 20080113411A1 · Sheffer et al. · 2008 [cited by applicant]
US 20080113412A1 · Sheffer et al. · 2008 [cited by applicant]
US 20080125574A1 · Sheffer et al. · 2008 [cited by applicant]
US 20080153747A1 · Alewood et al. · 2008 [cited by applicant]
US 20080161243A1 · Rosen et al. · 2008 [cited by applicant]
US 20080181903A1 · Bhaskar et al. · 2008 [cited by applicant]
US 20080182299A1 · Colocaru et al. · 2008 [cited by applicant]
US 20080194481A1 · Rosen et al. · 2008 [cited by applicant]
US 20080194682A1 · Golembo et al. · 2008 [cited by applicant]
US 20080227713A1 · Protter · 2008 [cited by applicant]
US 20080293632A1 · Rappold-Hoerbrand et al. · 2008 [cited by applicant]
US 20080312142A1 · Nakao et al. · 2008 [cited by applicant]
US 20090011997A1 · Peri et al. · 2009 [cited by applicant]
US 20090022728A1 · Lin · 2009 [cited by examiner]
US 20090023652A1 · Bell et al. · 2009 [cited by applicant]
US 20090053192A1 · Millan et al. · 2009 [cited by applicant]
US 20090069243A1 · Burnett, Jr. et al. · 2009 [cited by applicant]
US 20090092582A1 · Bogin et al. · 2009 [cited by applicant]
US 20090142347A1 · Millan · 2009 [cited by applicant]
US 20090170756A1 · Burnett, Jr. et al. · 2009 [cited by applicant]
US 20090221803A1 · Dall'Acqua et al. · 2009 [cited by applicant]
US 20090238814A1 · Tomatsu et al. · 2009 [cited by applicant]
US 20090240031A1 · Immer et al. · 2009 [cited by applicant]
US 20090247462A1 · Bogin et al. · 2009 [cited by applicant]
US 20090252729A1 · Farrington et al. · 2009 [cited by applicant]
US 20090258018A1 · Medich et al. · 2009 [cited by applicant]
US 20090275506A1 · Bakis et al. · 2009 [cited by applicant]
US 20090325195A1 · Davey et al. · 2009 [cited by applicant]
US 20100008979A1 · Tomatsu et al. · 2010 [cited by applicant]
US 20100055150A1 · Golembo et al. · 2010 [cited by applicant]
US 20100093678A1 · Della-Fera et al. · 2010 [cited by applicant]
US 20100160212A1 · Sheffer et al. · 2010 [cited by applicant]
US 20100168443A1 · Geysen · 2010 [cited by applicant]
US 20100184680A1 · Bevec · 2010 [cited by applicant]
US 20100197574A1 · Chen et al. · 2010 [cited by applicant]
US 20100204094A1 · Simari et al. · 2010 [cited by applicant]
US 20100204109A1 · Bevec · 2010 [cited by applicant]
US 20100204446A1 · Forssmann · 2010 [cited by applicant]
US 20100209958A1 · Nakao et al. · 2010 [cited by applicant]
US 20100216714A1 · James et al. · 2010 [cited by applicant]
US 20100221234A1 · Crine et al. · 2010 [cited by applicant]
US 20100240125A1 · Crine et al. · 2010 [cited by applicant]
US 20100249017A1 · Bevec et al. · 2010 [cited by applicant]
US 20100260706A1 · Bogin et al. · 2010 [cited by applicant]
US 20100261248A1 · Kim et al. · 2010 [cited by applicant]
US 20100297021A1 · Wendt et al. · 2010 [cited by applicant]
US 20100297119A1 · Crine · 2010 [cited by examiner]
US 20100305031A1 · Wakabayashi et al. · 2010 [cited by applicant]
US 20100305051A1 · Burnett, Jr. et al. · 2010 [cited by applicant]
US 20100310561A1 · Canada et al. · 2010 [cited by applicant]
US 20100311660A1 · Simari et al. · 2010 [cited by applicant]
US 20100317600A1 · Immer et al. · 2010 [cited by applicant]
US 20100331256A1 · Wendt et al. · 2010 [cited by applicant]
US 20110152194A1 · Burnett, Jr. et al. · 2011 [cited by applicant]
US 20110250187A1 · Tomatsu et al. · 2011 [cited by applicant]
US 20110269684A1 · Burnett, Jr. et al. · 2011 [cited by applicant]
US 20110300143A1 · Sly et al. · 2011 [cited by applicant]
US 20120088771A1 · Millan · 2012 [cited by applicant]
US 20120164142A1 · Crine et al. · 2012 [cited by applicant]
US 20130108635A1 · Crine et al. · 2013 [cited by applicant]
US 20130323244A1 · Crine et al. · 2013 [cited by applicant]
US 20140004096A1 · Nichols · 2014 [cited by applicant]
US 20140193388A1 · Velders et al. · 2014 [cited by applicant]
US 20140194484A1 · Coats et al. · 2014 [cited by applicant]
US 20150353633A1 · Kakkis et al. · 2015 [cited by applicant]
US 20160015784A1 · Shaw · 2016 [cited by examiner]
US 20160052968A1 · Crine et al. · 2016 [cited by applicant]
US 20160097100A1 · Trent et al. · 2016 [cited by applicant]
US 20170175094A1 · Hatch · 2017 [cited by applicant]
US 20170360899A1 · Marozsan et al. · 2017 [cited by applicant]
US 20180072986A1 · Park et al. · 2018 [cited by applicant]
US 20180230445A1 · Jaluria et al. · 2018 [cited by applicant]
US 20190043501A1 · Ramaci · 2019 [cited by applicant]
US 20190099473A1 · Fujita et al. · 2019 [cited by applicant]
US 20200101141A1 · Moseley et al. · 2020 [cited by applicant]
US 20200121767A1 · Tomazos et al. · 2020 [cited by applicant]
US 20200224182A1 · Rajendran et al. · 2020 [cited by applicant]
US 20200306350A1 · Fujita et al. · 2020 [cited by applicant]
US 20210317425A1 · Godawat et al. · 2021 [cited by applicant]
US 20220154155A1 · Godawat et al. · 2022 [cited by applicant]
US 20230372456A1 · Petryk et al. · 2023 [cited by applicant]
US 20240382568A1 · Voegtli et al. · 2024 [cited by applicant]
CA 3161266A1 · 2021 [cited by applicant]
CN 103153344A · 2013 [cited by applicant]
EP 0478797B1 · 1995 [cited by applicant]
EP 0769554A2 · 1997 [cited by applicant]
EP 0466174B1 · 1997 [cited by applicant]
EP 0475394B1 · 1997 [cited by applicant]
EP 0466175B1 · 1998 [cited by applicant]
EP 0477971B1 · 1998 [cited by applicant]
EP 0475290B1 · 1998 [cited by applicant]
EP 0475291B1 · 1998 [cited by applicant]
EP 0497368B1 · 2002 [cited by applicant]
EP 1492567 · 2003 [cited by applicant]
EP 1488802A2 · 2004 [cited by applicant]
EP 1502604A1 · 2005 [cited by applicant]
EP 1623994A2 · 2006 [cited by applicant]
EP 1759710A1 · 2007 [cited by applicant]
EP 0771875B1 · 2008 [cited by applicant]
EP 1985697A1 · 2008 [cited by applicant]
EP 2158319A0 · 2010 [cited by applicant]
EP 1759001B1 · 2011 [cited by applicant]
EP 2158319B1 · 2011 [cited by applicant]
EP 3250227A2 · 2017 [cited by applicant]
JP 870875A · 1996 [cited by applicant]
JP 2000327583A · 2000 [cited by applicant]
JP 2002541776A · 2002 [cited by applicant]
JP 2007511209A · 2007 [cited by applicant]
JP 2007533669A · 2007 [cited by applicant]
JP 2007537725A · 2007 [cited by applicant]
JP 2010501026A · 2010 [cited by applicant]
JP 2010526543A · 2010 [cited by applicant]
JP 2010530222A · 2010 [cited by applicant]
JP 2011504506A · 2011 [cited by applicant]
JP 2015502336A · 2015 [cited by applicant]
JP 2017505128A · 2017 [cited by applicant]
RU 2708068C2 · 2019 [cited by applicant]
WO WO9220371A1 · 1992 [cited by applicant]
WO WO9420534A1 · 1994 [cited by applicant]
WO WO9505456A1 · 1995 [cited by applicant]
WO WO9513296A1 · 1995 [cited by applicant]
WO WO9533769A1 · 1995 [cited by applicant]
WO WO9817690A1 · 1998 [cited by applicant]
WO WO9835703A2 · 1998 [cited by applicant]
WO WO9946283A1 · 1999 [cited by applicant]
WO WO0018954A2 · 2000 [cited by applicant]
WO WO0050580A2 · 2000 [cited by applicant]
WO WO0053755A2 · 2000 [cited by applicant]
WO WO0064486A2 · 2000 [cited by applicant]
WO WO0069900A2 · 2000 [cited by applicant]
WO WO0136620A2 · 2001 [cited by applicant]
WO WO0144284A2 · 2001 [cited by applicant]
WO WO0180890A2 · 2001 [cited by applicant]
WO WO0215918A2 · 2002 [cited by applicant]
WO WO0247871A1 · 2002 [cited by applicant]
WO WO02067639A1 · 2002 [cited by applicant]
WO WO02068579A2 · 2002 [cited by applicant]
WO WO02074234A2 · 2002 [cited by applicant]
WO WO03074082A1 · 2003 [cited by applicant]
WO WO03079979A2 · 2003 [cited by applicant]
WO WO03092581A2 · 2003 [cited by applicant]
WO WO03094835A2 · 2003 [cited by applicant]
WO WO2004011498A2 · 2004 [cited by applicant]
WO WO2004022579A2 · 2004 [cited by applicant]
WO WO2004046194A2 · 2004 [cited by applicant]
WO WO2004047871A2 · 2004 [cited by applicant]
WO WO2004062555A2 · 2004 [cited by applicant]
WO WO2004074320A2 · 2004 [cited by applicant]
WO WO2004094460A2 · 2004 [cited by applicant]
WO WO2005000095A2 · 2005 [cited by applicant]
WO WO2005007809A2 · 2005 [cited by applicant]
WO WO2005042034A1 · 2005 [cited by applicant]
WO WO2005047337A1 · 2005 [cited by applicant]
WO WO2005070446A1 · 2005 [cited by applicant]
WO WO2005072055A2 · 2005 [cited by applicant]
WO WO2005087802A2 · 2005 [cited by applicant]
WO WO2005094890A1 · 2005 [cited by applicant]
WO WO2005098490A1 · 2005 [cited by applicant]
WO WO2005103263A1 · 2005 [cited by applicant]
WO WO2005105156A1 · 2005 [cited by applicant]
WO WO2005110435A1 · 2005 [cited by applicant]
WO WO2006005140A2 · 2006 [cited by applicant]
WO WO2006026663A1 · 2006 [cited by applicant]
WO WO2006039480A2 · 2006 [cited by applicant]
WO WO2006060641A2 · 2006 [cited by applicant]
WO WO2006110743A1 · 2006 [cited by applicant]
WO WO2006116260A2 · 2006 [cited by applicant]
WO WO2007041645A2 · 2007 [cited by applicant]
WO WO2007071295A1 · 2007 [cited by applicant]
WO WO2007097923A2 · 2007 [cited by applicant]
WO WO2007130113A2 · 2007 [cited by applicant]
WO WO2008021872A1 · 2008 [cited by applicant]
WO WO2008030558A2 · 2008 [cited by applicant]
WO WO2008031045A2 · 2008 [cited by applicant]
WO WO2008053362A2 · 2008 [cited by applicant]
WO WO2008058016A2 · 2008 [cited by applicant]
WO WO2008079995A2 · 2008 [cited by applicant]
WO WO2008088422A2 · 2008 [cited by applicant]
WO WO2008109903A1 · 2008 [cited by applicant]
WO WO2008133511A2 · 2008 [cited by applicant]
WO WO2008136611A1 · 2008 [cited by applicant]
WO WO2008138131A1 · 2008 [cited by applicant]
WO WO2008154226A1 · 2008 [cited by applicant]
WO WO2009006520A1 · 2009 [cited by applicant]
WO WO2009015011A1 · 2009 [cited by applicant]
WO WO2009023270A2 · 2009 [cited by applicant]
WO WO2009006732A9 · 2009 [cited by applicant]
WO WO2009033680A2 · 2009 [cited by applicant]
WO WO2009033724A1 · 2009 [cited by applicant]
WO WO2009033796A1 · 2009 [cited by applicant]
WO WO2009033807A2 · 2009 [cited by applicant]
WO WO2009034134A2 · 2009 [cited by applicant]
WO WO2009036448A2 · 2009 [cited by applicant]
WO WO2009040030A1 · 2009 [cited by applicant]
WO WO2009040031A2 · 2009 [cited by applicant]
WO WO2009040083A2 · 2009 [cited by applicant]
WO WO2009046861A1 · 2009 [cited by applicant]
WO WO2009058322A1 · 2009 [cited by applicant]
WO WO2009067639A2 · 2009 [cited by applicant]
WO WO2009086126A2 · 2009 [cited by applicant]
WO WO2009090553A2 · 2009 [cited by applicant]
WO WO2009142307A1 · 2009 [cited by applicant]
WO WO2009149161A9 · 2009 [cited by applicant]
WO WO2009156481A1 · 2009 [cited by applicant]
WO WO2009158035A2 · 2009 [cited by applicant]
WO WO2010002583A2 · 2010 [cited by applicant]
WO WO2010011096A2 · 2010 [cited by applicant]
WO WO2010048308A2 · 2010 [cited by applicant]
WO WO2010078325A2 · 2010 [cited by applicant]
WO WO2010082804A2 · 2010 [cited by applicant]
WO WO2010117760A2 · 2010 [cited by applicant]
WO WO2010129655A2 · 2010 [cited by applicant]
WO WO2010135541A2 · 2010 [cited by applicant]
WO WO2011130229A1 · 2011 [cited by applicant]
WO WO2011134084A1 · 2011 [cited by applicant]
WO WO2012088608A1 · 2012 [cited by applicant]
WO WO2012099851A2 · 2012 [cited by applicant]
WO WO2013058833 · 2013 [cited by examiner]
WO WO2013058833A1 · 2013 [cited by applicant]
WO WO2013059491A1 · 2013 [cited by applicant]
WO WO2013071262A1 · 2013 [cited by applicant]
WO WO2015112015A1 · 2015 [cited by applicant]
WO WO2015112017A1 · 2015 [cited by applicant]
WO WO2016007873A1 · 2016 [cited by applicant]
WO WO2016090251A1 · 2016 [cited by applicant]
WO WO2016123342A2 · 2016 [cited by applicant]
WO WO2016153191A1 · 2016 [cited by applicant]
WO WO2017031114A1 · 2017 [cited by applicant]
WO WO2017058822A1 · 2017 [cited by applicant]
WO WO2017074466A1 · 2017 [cited by applicant]
WO WO2017155569A1 · 2017 [cited by applicant]
WO WO2017171871A1 · 2017 [cited by applicant]
WO WO2017173395A1 · 2017 [cited by applicant]
WO WO2017173413A1 · 2017 [cited by applicant]
WO WO2017214130A1 · 2017 [cited by applicant]
WO WO2018004517A1 · 2018 [cited by applicant]
WO WO2018035420A1 · 2018 [cited by applicant]
WO WO2018164995A1 · 2018 [cited by applicant]
WO WO2019164978A1 · 2019 [cited by applicant]
WO WO2019183208A1 · 2019 [cited by applicant]
WO WO2019190752A1 · 2019 [cited by applicant]
WO WO2020247421A1 · 2020 [cited by applicant]
WO WO2021119218A1 · 2021 [cited by applicant]
An et al. (Nov. 2009). lgG2m4, an engineered antibody isotype with reduced Fc function. In MAbs (vol. 1, No. 6, pp. 572-579). Taylor & Francis. (Year: 2009). [cited by examiner]
Komaru, K., Ishida-Okumura, Y., Numa-Kinjoh, N., Hasegawa, T., & Oda, K. (2019). Molecular and cellular basis of hypophosphatasia. Journal of oral biosciences, 61(3), 141-148. (Year: 2019). [cited by examiner]
Sharma, U., Pal, D., & Prasad, R. (2014). Alkaline phosphatase: an overview. Indian Journal of Clinical Biochemistry, 29(3), 269-278. (Year: 2014). [cited by examiner]
Di Mauro, S., Manes, T., Hessle, L., Kozlenkov, A., Pizauro JR, J. M., Hoylaerts, M. F., & Millán, J. L. (2002). Kinetic characterization of hypophosphatasia mutations with physiological substrates. Journal of Bone and … [cited by examiner]
Komaru K, Ishida-Okumura Y, Numa-Kinjoh N, Hasegawa T, Oda K. Molecular and cellular basis of hypophosphatasia. J Oral Biosci. Sep. 2019;61(3):141-148. doi: 10.1016/j.job.2019.07.003. Epub Aug. 8, 2019. PMID: 31400546. … [cited by examiner]
Clustal Omega (2023) was used to obtain the multiple sequence alignments provided in the office action appendix. The alignments were retrieved on Jan. 10, 2025 and Jan. 8, 2025 from https://www.ebi.ac.uk/jdispatcher/msa… [cited by examiner]
International Search Report and Written Opinion for International Patent Application No. PCT/US20/64140, mailed Apr. 23, 2021 (16 pages). [cited by applicant]
Kishnani et al., “Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia,” Bone. 121:149-162 (2019). [cited by applicant]
Alexion Pharmaceuticals, “Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP),” ClinicalTrials.gov. NCT00739505, <https://www.cli… [cited by applicant]
Alexion Pharmaceuticals, “Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP),” ClinicalTrials.gov. NCT01163149, <https://clinicaltrials.gov/ct2/show/NCT01163149>, last updat… [cited by applicant]
Alexion Pharmaceuticals, “Strensiq™ (asfotase alfa) for injection,” retrieved from <globalgenes.org/2015/11/05/alexion-announces-fda-approval-for--strensiq/?gclid=CjwKCAjwwqaGBhBKEiwAMk-FtFQOKvuVN-WmNcDVyu9Q9X3f6QB-VOTw… [cited by applicant]
European Medicines Agency, “Strensiq: Asfotase Alfa,” <www.ema.europa.eu/en/medicines/human/EPAR/strensiq>, last updated Mar. 25, 2021 (8 pages). [cited by applicant]
Hofmann et al., “Efficacy and safety of asfotase alfa in infants and young children with hypophosphatasia: a phase 2 open-label study,” J Clin Endocrinol Metab. 104(7): 2735-2747 (2019) (14 pages). [cited by applicant]
Kim et al., “CHO cells in biotechnology for production of recombinant proteins: current state and further potential,” Appl Microbiol Biotechnol. 93(3):917-30 (2012). [cited by applicant]
McCormack et al., “Is bigger better? An argument for very low starting doses,” CMAJ. 183(1):65-9 (2011). [cited by applicant]
Rush, “Childhood hypophosphatasia: to treat or not to treat,” Orphanet J Rare Dis. 13(1):116 (2018) (5 pages). [cited by applicant]
Phillips et al., “Clinical Outcome Assessments: Use of Normative Data in a Pediatric Rare Disease,” Value Health. 21(5):508-514 (2018). [cited by applicant]
“Effects of feeding strategy on CHO cell performance in fed-batch cultures using HyClone ActiPro medium and Cell Boost 7a and 7b supplements,” Cytiva, <http://www.processdevelopmentforum.com/posters/effects-of-feeding-s… [cited by applicant]
Witkowski et al., “Conversion of a beta-ketoacyl synthase to a malonyl decarboxylase by replacement of the active-site cysteine with glutamine,” Biochemistry. 38(36):11643-50 (1999). [cited by applicant]
Whisstock et al., “Prediction of protein function from protein sequence and structure,” Q Rev Biophys. 36(3):307-40 (2003). [cited by applicant]
Fu-Hang et al., “Preliminary study on the effect of Zn2+ on the activities of peptidase and alkaline phosphatase,” Marine Sciences. 27(3):64-65 (2003). [cited by applicant]
Office Action for Chinese Patent Application No. 201680048588.5, mailed Jan. 18, 2021 (13 pages). [cited by applicant]
Dutta et al., “Men and mice: Relating their ages,” Life Sci. 152:244-8 (2015). [cited by applicant]
Zhang et al., “Engineering [cited by applicant]
Nangia et al., “Disorders of Calcium Metabolism in Newborns,” Journal of Neonatology. 17(2):43-49 (2003). [cited by applicant]
Kochanowski et al., “Medium and feed optimization for fed-batch production of a monoclonal antibody in CHO cells,” BMC Proc. 5(Suppl 8):P75 (2011) (3 pages). [cited by applicant]
“Xcellerex™ XDR cell culture bioreactor systems,” GE Healthcare Life Sciences, retrieved from <https://www.cytivallifesciences.co.jp/catalog/pdf/29092925AA.pdf>, published Feb. 2014 (4 pages). [cited by applicant]
Yagasaki et al., “Animal Cell Technology: Basic & Applied Aspects,” Proceedings of the Fifteenth Annual Meeting of the Japanese Association for Animal Cell Technology (JAACT), vol. 13, Fuchu, Nov. 11-15, 2002 (461 pages… [cited by applicant]
Kozlenkov et al., “Residues determining the binding specificity of uncompetitive inhibitors to tissue-nonspecific alkaline phosphatase,” J Bone Miner Res. 19(11):1862-72 (2004). [cited by applicant]
NCBI Protein Database Accession No. NM_000478, retrieved on Feb. 23, 2021 (7 pages). [cited by applicant]
Pradhan et al., “Exposure-Response Modeling and Simulation to Support Evaluation of Efficacious and Safe Exposure and Dose Range for Asfotase alfa in Patients with Hypophosphatasia,” ASBMR 2015 Annual Meeting Abstracts.… [cited by applicant]
Abbruzzese, L., “The Tinetti Performance-Oriented Mobility Assessment Tool,” Am J Nursing. 98(12):16J-16L (1998) (3 pages). [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US20/64140, mailed Apr. 23, 2021 (70 pages). [cited by applicant]
Ali et al., “Isolation and characterization of calcifying matrix vesicles from epiphyseal cartilage,” Proc Natl Acad Sci USA. 67(3):1513-20 (1970). [cited by applicant]
Anderson et al., “Pyrophosphate stimulation of calcium uptake into cultured embryonic bones. Fine structure of matrix vesicles and their role in calcification,” Dev Biol. 34:211-227 (1973). [cited by applicant]
Anderson et al., “Sustained osteomalacia of long bones despite major improvement in other hypophosphatasia-related mineral deficits in tissue nonspecific alkaline phosphatase/nucleotide pyrophosphatase phosphodiesterase… [cited by applicant]
Anderson et al., “The role of matrix vesicles in growth plate development and biomineralization,” Front Biosci. 10:822-37 (2005). [cited by applicant]
Beertsen et al., “Root development in mice lacking functional tissue non-specific alkaline phosphatase gene: Inhibition of acellular cementum formation,” J Dent Res. 78(6):1221-1229 (1999) (10 pages). [cited by applicant]
Bennett et al., “Extracellular domain-IgG fusion proteins for three human natriuretic peptide receptors,” J Biol Chem. 266(34):23060-23067 (1991). [cited by applicant]
Bernard, “Ultrastructural localization of alkaline phosphatase in initial intramembranous osteogenesis,” Clin Orthop Relat Res. 135:218-225 (1978). [cited by applicant]
Bonilla, “Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes,” Immunol Allergy Clin N Am. 28:803-819 (2008). [cited by applicant]
Byers et al., “Effect of enzyme replacement therapy on bone formation in a feline model of mucopolysaccharidosis type VI,” Bone. 21(5):425-431 (1997). [cited by applicant]
Cameron et al., “Minireview: Natriuretic peptides during development of the fetal heart and circulation,” Endocrinology. 144(6):2191-2194 (2003). [cited by applicant]
Clemens et al., “Pharmacokinetics and biological actions of subcutaneously administered human brain natriuretic peptide,” J Pharmacol Exp Ther. 287(1):67-71 (1998). [cited by applicant]
Cited By (1)
US 12,611,447